Gulfo Might Reevaluate Negotiated User Fees If Selected US FDA Commish
Executive Summary
Joseph Gulfo, a former medtech industry CEO and vocal FDA critic, is the latest candidate apparently being considered for FDA commissioner. In an interview with Medtech Insight, he outlines his worldview and interest in pushing aggressively against increasing the FDA "body of law."
You may also be interested in...
Obamacare Repeal May Be Delaying User-Fee Bills, Rep. DeGette Says
The House Energy and Commerce Committee Democrat says few in-depth member talks about user-fee bills have taken place because of a focus on Affordable Care Act repeal and replacement.
Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking
O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.
MDUFA IV Takes Shape: A Catalogue Of Draft Commitments
More specific details have emerged about the agreement "in principle" announced last week by FDA and industry negotiators on the next round of the medical device user-fee program, which will extend from fiscal years 2018 through 2022.